Arcturus Therapeutics Hits 52-Week Low at $5.85 Amid Financial Struggles

Arcturus Therapeutics Holdings, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 5.85 on November 20, 2025. This significant decline reflects a challenging year for the company, which has seen its stock price plummet by 81.5% over the past year, starkly contrasting with the S&P 500's positive performance of 12.26% during the same period.
The company's financial metrics indicate ongoing difficulties, with a negative return on equity of -10.01% and a debt-to-equity ratio of -1.07. Arcturus has reported a decline in net sales of 3.8%, with recent quarterly results showing a net sales figure of USD 24.51 million, down 25.31%. The pre-tax profit has also taken a hit, falling by 64.11% to a loss of USD 5.35 million.

With a market capitalization of USD 484 million and a price-to-book ratio of 2.10, Arcturus Therapeutics is navigating a challenging landscape, marked by negative EBITDA and underperformance relative to broader market indices.